The Impact of Nucleolar Stress on Thymocyte Development and T Cell Acute Lymphoblastic Leukemia Transformation
核仁应激对胸腺细胞发育和 T 细胞急性淋巴细胞白血病转化的影响
基本信息
- 批准号:9908655
- 负责人:
- 金额:$ 3.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-09 至 2021-09-08
- 项目状态:已结题
- 来源:
- 关键词:Acute Lymphocytic LeukemiaAcute T Cell LeukemiaAddressAdultBindingBiogenesisBone MarrowCDKN2A geneCell LineCell LineageCellsCellular StressChildhoodChimera organismChimerismClone CellsCytoplasmDataEventFeedbackGenesGeneticGoalsGrowthHematopoieticHematopoietic NeoplasmsHematopoietic stem cellsInduced MutationLymphoidMDM2 geneMessenger RNAModelingMolecularMusMutationMyelogenousMyeloproliferative diseaseNOTCH1 geneNuclearPathogenesisPathway interactionsPatientsPlayProtein BiosynthesisResearchRetroviridaeRibosomal ProteinsRibosomesRoleSignal TransductionStem cellsStressT-Cell DevelopmentT-LymphocyteTP53 geneTestingTherapeuticThymocyte DevelopmentTransplantationXenograft procedureacute T-cell lymphoblastic leukemia cellbasec-myc Genescongenicdesignexperimental studygene inductioninsightknock-downleukemic transformationnotch proteinnovelnovel therapeuticsprogenitorribosome profilingsingle-cell RNA sequencingtargeted agenttranscriptome
项目摘要
Project Summary/Abstract
T-ALL represents 10-15% of pediatric and 20-25% of adult cases of acute lymphoblastic leukemia. Activating
mutations of NOTCH1 are present in ~60% of cases of T-ALL and are thought to induce leukemic transformation,
in part, by activating c-Myc (Myc). Myc induces ribosome biogenesis, which can trigger the nucleolar stress
pathway. This is an evolutionarily conserved pathway that includes the translocation of ribosome proteins, RPL5,
RPL11, and RPL22 to the nuclear cytoplasm where they bind and alter the activity of p14ARF (ARF) and MDM2,
which in turn activates p53, inducing a growth arrest. To overcome this negative feedback loop, over 80% of T-
ALL carry biallelic deletions of the CDKN2A (encoding for P16INK4A and ARF). In addition, ~17% of T-ALL carry
mutations of RPL5, RPL11, or RPL22. Based on this genetic evidence, we hypothesize that Notch signaling
induces nucleolar stress in T-ALL and that inactivation of the nucleolar stress pathway is essential to
the molecular pathogenesis of T-ALL. The following specific aims are proposed to test this hypothesis.
Aim 1. To determine whether induction of nucleolar stress during normal T-cell development
selects for clones carrying mutations in CDKN2A. Notch signaling plays an essential role in normal early T-
cell development. We hypothesize that induction of nucleolar stress during early T-cell development selects for
T-cell clones carrying mutations of CDKN2A (or RPL genes). To test this hypothesis, we will isolate T-cell
progenitors/precursors from wildtype mice and analyze for signs of nucleolar stress. We also will generate Arf
or Ink4a deficient mixed bone marrow chimeras and assess donor chimerism. We predict that nucleolar stress
in T-cell progenitors/precursors will result in the selective expansion of Arf deficient cells in the T-cell lineage.
Aim 2. To determine whether activating Notch1 mutations induce nucleolar stress in T cell
progenitors. We will assess the impact of the enforced expression of NOTCH1 mutations found in T-ALL on
ribosome biogenesis and induction of nucleolar stress using the MOLM13 cell line and primary murine T-cells.
In parallel studies, we also will knock-down NOTCH1 expression in several T-ALL xenografts. In each case,
nucleolar stress will be assessed
项目摘要/摘要
T-ALL代表10-15%的小儿和20-25%的成年急性淋巴细胞白血病病例。激活
Notch1的突变存在于〜60%的T-ALL病例中,被认为会诱导白血病转化,
部分通过激活C-MYC(MYC)。 MYC诱导核糖体生物发生,可以触发核仁应力
路径。这是一种进化保守的途径,包括核糖体蛋白Rpl5,
RPL11和RPL22到核细胞质,它们结合并改变了p14arf(ARF)和MDM2的活性,
这反过来激活了p53,引起了生长停滞。为了克服这种负反馈循环,超过80%的t-
所有人都带有CDKN2A的双重缺失(编码P16INK4A和ARF)。此外,约有17%的T-All随身携带
RPL5,RPL11或RPL22的突变。基于此遗传证据,我们假设Notch信号传导
诱导T-ALL诱导核仁应力,并且核仁应力途径的失活对于
T-ALL的分子发病机理。提出了以下特定目的来检验这一假设。
目的1。确定在正常T细胞发育过程中是否诱导核仁应力
选择在CDKN2A中携带突变的克隆。 Notch信号在正常的早期T-中起着至关重要的作用
细胞发育。我们假设在早期T细胞发育过程中诱导核仁应力会选择
带有CDKN2A突变(或RPL基因)突变的T细胞克隆。为了检验这一假设,我们将隔离T细胞
野生型小鼠的祖/前体,分析核仁应力的迹象。我们还将生成ARF
或Ink4a缺乏混合骨髓嵌合体并评估供体嵌合体。我们预测核仁应力
在T细胞祖细胞/前体中,将导致T细胞谱系中ARF缺陷细胞的选择性扩展。
目标2。确定激活Notch1突变是否诱导T细胞中的核仁应力
祖先。我们将评估T-All中发现Notch1突变的强制表达的影响
核糖体生物发生和使用Molm13细胞系和原代鼠T细胞诱导核仁应力。
在平行研究中,我们还将在几个T-All异种移植物中敲低Notch1的表达。在每种情况下,
核仁应力将被评估
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH RYAN KRAMBS其他文献
JOSEPH RYAN KRAMBS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH RYAN KRAMBS', 18)}}的其他基金
The Impact of Nucleolar Stress on Thymocyte Development and T Cell Acute Lymphoblastic Leukemia Transformation
核仁应激对胸腺细胞发育和 T 细胞急性淋巴细胞白血病转化的影响
- 批准号:
10014587 - 财政年份:2019
- 资助金额:
$ 3.09万 - 项目类别:
相似国自然基金
活性脂质Arlm-1介导的自噬流阻滞在儿童T细胞急性淋巴细胞白血病化疗耐药逆转中的作用机制研究
- 批准号:82300182
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PHF6突变通过相分离调控YTHDC2-m6A-SREBP2信号轴促进急性T淋巴细胞白血病发生发展的机制研究
- 批准号:82370165
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
肠道菌群代谢产物乳酸通过调控Miro1乳酸化修饰介导线粒体转移在急性髓系白血病T细胞耗竭中的作用及机制研究
- 批准号:82370173
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
骨髓微环境PD-L1维持急性T淋巴细胞白血病中白血病干细胞功能的机制研究
- 批准号:
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:
CLEC12A介导急性髓系白血病T细胞免疫抑制和髓外浸润的作用及机制研究
- 批准号:82302077
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
选择性剪接的细胞表面蛋白作为白血病发生的驱动因素和免疫治疗的靶点
- 批准号:
10648346 - 财政年份:2023
- 资助金额:
$ 3.09万 - 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
- 批准号:
10651082 - 财政年份:2023
- 资助金额:
$ 3.09万 - 项目类别:
Bridging the gap: joint modeling of single-cell 1D and 3D genomics
弥合差距:单细胞 1D 和 3D 基因组学联合建模
- 批准号:
10572539 - 财政年份:2023
- 资助金额:
$ 3.09万 - 项目类别:
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneic hematopoietic cell transplantation
靶向CD83减少同种异体造血细胞移植后白血病复发和GVHD
- 批准号:
10573570 - 财政年份:2023
- 资助金额:
$ 3.09万 - 项目类别:
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies
靶向 CD19、CD20 和 CD22 的三特异性 CAR-T 细胞治疗 B 细胞恶性肿瘤
- 批准号:
10735096 - 财政年份:2023
- 资助金额:
$ 3.09万 - 项目类别: